American Journal of Kidney Diseases
Volume 54, Issue 6 , Pages 996-999 , December 2009

Hypertension in Hemodialysis Patients: The Role of Antihypertensive Medications

  • Dana C. Miskulin, MD, MS

      Affiliations

    • Tufts Medical Center, Boston, Massachusetts
    • Corresponding Author InformationAddress correspondence to Dana C. Miskulin, MD, MS, Division of Nephrology, Tufts Medical Center Box 391, 800 Washington St, Boston, MA 02111
    • ,
  • Philip G. Zager, MD

      Affiliations

    • University of New Mexico Health Sciences Center, Albuquerque, New Mexico

References 

  1. Agarwal R, Nissenson AR, Batlle D, et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115(4):291–297
  2. Heerspink HJL, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009;373(9668):1009–1015
  3. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438–1444
  4. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis (A randomized, controlled study). Ann Intern Med. 2003;139(2):105–112
  5. Cice G, Di Benedetto A, D'Isa S, D'Andrea A, De Gregoria P, Calabro R. Effect of telmisartan added to angiotensin converting enzyme inhibitors in reducing morbidity and mortality in haemodialysis patients with chronic heart failure [abstract]. J Hypertens Suppl. 2006;24:S56
  6. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study. Nephrol Dial Transplant. 2006;21(9):2507–2512
  7. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70(7):1318–1324
  8. Nakao N, Hasegawa H, Fujimori A, Seno H, Toriyama T, Kawahare H. Effects of combined β-blockade and anti-aldosterone antagonist treatment for cardiovascular prevention in patients receiving maintenance dialysis. [abstract] J Am Soc Nephrol. 2007;18:709A
  9. Suzuki H, Kanno Y, Sugahara S, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008;52(3):501–506
  10. Tepel M, Hopfenmueller W, Scholze A, Maier A, Zidek W. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant. 2008;23(11):3605–3612
  11. Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol. 2007;2(6):1228–1234
  12. Charra B, Bergstrom J, Scribner BH. Blood pressure control in dialysis patients: importance of the lag phenomenon. Am J Kidney Dis. 1998;32(5):720–724
  13. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291–1297
  14. Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999;33(3):507–517
  15. Zager PG, Nikolic J, Brown RH, et al. “U” curve association of blood pressure and mortality in hemodialysis patients. Kidney Int. 1998;54(2):561–569
  16. Stidley CA, Hunt WC, Tentori F, et al. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol. 2006;17(2):513–520
  17. Agarwal R, Alborzi P, Satyan S, et al. Dry-Weight Reduction in Hypertensive Hemodialysis Patients (DRIP): a randomized, controlled trial. Hypertension. 2009;53(3):500–507
  18. London G. Controversy on optimal blood pressure on haemodialysis: lower is not always better. Nephrol Dial Transplant. 2001;16(3):475–478
  19. Dasselaar JJ, Slart RHJA, Knip M, et al. Haemodialysis is associated with a pronounced fall in myocardial perfusion. Nephrol Dial Transplant. 2009;24(2):604–610
  20. Hothi DK, Rees L, Marek J, et al. Pediatric myocardial stunning underscores the cardiac toxicity of conventional hemodialysis treatments. Clin J Am Soc Nephrol. 2009;4(4):790–797
  21. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease (Modification of Diet in Renal Disease Study Group). N Engl J Med. 1994;330(13):877–884
  22. Wright JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421–2431
  23. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med. 2005;142(5):342–351
  24. Agarwal R. Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(4):830–837
  25. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, et al. Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease. Nephrol Dial Transplant. 2006;21(5):1257–1262
  26. Weiner DE, Tighiouart H, Levey AS, et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol. 2007;18(3):960–966
  27. Cushman S, Grimm R, Cutler J, et al. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Am J Cardiol. 2007;99(12A):44i–55i

 Originally published online as doi: 10.1053/j.ajkd.2009.08.002 on October 12, 2009.

PII: S0272-6386(09)01047-6

doi: 10.1053/j.ajkd.2009.08.002

American Journal of Kidney Diseases
Volume 54, Issue 6 , Pages 996-999 , December 2009

Article Tools